Kissei Pharmaceutical Co (4547) AI Stock Analysis

• Market Cap: ¥164.20B
• Dividend Yield: 2.86%
• Average Volume (3M): 60.08K
• Price to Earnings (P/E): 11.7
• Beta (1Y): 0.47
• Revenue Growth: 13.11%
• EPS Growth: 41.64%
• Country: JP
• Employees: 1,779
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 78.93
• Shares Outstanding: 46,541,985
• 10 Day Avg. Volume: 75,230
• 30 Day Avg. Volume: 60,080
• PEG Ratio: 1.25
• Price to Book (P/B): 0.80
• Price to Sales (P/S): 1.90
• P/FCF Ratio: 83.28
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: ¥4,473.00 ▲(7.27% Upside)

Kissei Pharmaceutical's strong financial performance is the most significant factor, supported by stable revenue growth and profitability. However, technical indicators suggest bearish momentum, and valuation metrics indicate moderate attractiveness. The absence of earnings call and corporate events data limits additional insights.

Kissei Pharmaceutical Co Business Overview & Revenue Model

Company Description

Kissei Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company primarily engaged in the research, development, manufacturing, and marketing of prescription drugs. The company operates in various sectors, including diabetes management, urology, and central nervous system disorders, and focuses on innovative therapies that address unmet medical needs. Kissei's core products include medications for diabetes such as the GLP-1 receptor agonist and various other treatments that enhance the quality of life for patients with chronic conditions.

How the Company Makes Money

Kissei Pharmaceutical generates revenue primarily through the sale of its pharmaceutical products, which are distributed both domestically in Japan and internationally. The company’s revenue model is based on direct sales of prescription medications to healthcare providers and hospitals. Key revenue streams include sales of diabetes medications, urological therapies, and treatments for neurological conditions. Additionally, Kissei engages in partnerships and collaborations with other pharmaceutical companies and research institutions, which can lead to shared development costs and potential royalties from co-developed products. The company also benefits from licensing agreements, where it licenses its drug formulations or technologies to other firms, creating additional revenue opportunities.

Kissei Pharmaceutical Co Financial Statement Overview

Summary

Kissei Pharmaceutical shows strong financial performance with robust revenue growth and improved profitability. The balance sheet is stable with low leverage, and cash flow improvements are promising, though free cash flow generation needs enhancement.

Income Statement

Kissei Pharmaceutical experienced robust revenue growth from 2024 to 2025 with a growth rate of 16.85%. The gross profit margin remained stable at around 49.9%, while the net profit margin improved to 13.54%. EBIT and EBITDA margins indicate strong operational efficiency, with a noticeable recovery in EBIT margin to 6.54% after a prior negative performance. Overall, the company shows solid profitability and growth trajectory despite past volatility.

Balance Sheet

The balance sheet reflects financial stability with a low debt-to-equity ratio of 0.0061 and a high equity ratio of 85.63%. Return on equity is commendable at 5.72%, highlighting effective use of shareholders' equity. These metrics indicate strong financial health and low leverage, providing a cushion against market fluctuations.

Cash Flow

Cash flows have improved significantly, with a positive shift in free cash flow and operating cash flow from previous negative values. The operating cash flow to net income ratio is 0.55, showcasing a decent conversion of income to cash. However, the free cash flow to net income ratio remains low at 0.17, suggesting room for improvement in cash generation relative to net income.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	89.36B	88.33B	75.58B	67.49B	65.38B	69.04B
Gross Profit	44.26B	44.06B	37.34B	32.38B	31.24B	32.72B
EBITDA	16.86B	20.25B	18.72B	17.81B	20.26B	10.65B
Net Income	12.37B	11.96B	11.16B	10.53B	12.92B	5.29B
Balance Sheet
Total Assets	243.67B	244.06B	260.93B	221.20B	238.09B	268.86B
Cash, Cash Equivalents and Short-Term Investments	48.75B	48.65B	45.93B	49.60B	53.15B	44.45B
Total Debt	1.28B	1.28B	1.34B	1.49B	1.64B	1.74B
Total Liabilities	35.44B	33.93B	39.80B	26.39B	35.91B	48.91B
Stockholders Equity	207.09B	209.00B	220.03B	193.90B	201.38B	219.31B
Cash Flow
Free Cash Flow	0.00	2.01B	-3.51B	-9.23B	-386.00M	-4.03B
Operating Cash Flow	0.00	6.52B	-1.68B	-6.68B	1.53B	-2.54B
Investing Cash Flow	0.00	4.95B	8.69B	6.00B	10.78B	-9.33B
Financing Cash Flow	0.00	-9.32B	-10.01B	-3.42B	-2.76B	-4.00B

Kissei Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4170.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4547, the sentiment is Negative. The current price of 4170 is above the 20-day moving average (MA) of 4107.75, below the 50-day MA of 4251.46, and above the 200-day MA of 3973.40, indicating a neutral trend. The MACD of -70.49 indicates Positive momentum. The RSI at 37.67 is Neutral, neither overbought nor oversold. The STOCH value of 48.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4547.

Kissei Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4521	80 Outperform	¥132.55B	11.12	8.77%	4.62%	31.19%	72.28%
4553	68 Neutral	¥137.16B	8.57	9.60%	2.87%	11.11%	-5.42%
4551	65 Neutral	―	―	―	―	10.91%	2.93%
4547	63 Neutral	¥164.20B	11.74	6.57%	2.86%	13.11%	41.64%
4534	62 Neutral	¥105.15B	16.31	5.11%	2.63%	4.35%	48.30%
4887	57 Neutral	¥182.53B	199.01	―	2.89%	3.52%	-95.28%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Kissei Pharmaceutical Co Corporate Events

Kissei’s Linzagolix Gains Marketing Approval in Taiwan

Kissei Pharmaceutical Co., Ltd. announced that its GnRH antagonist, Linzagolix, has been approved for marketing in Taiwan under the brand name Yselty, for the treatment of uterine fibroids. This approval, granted to Synmosa Biopharma Corporation, marks a significant step in providing new treatment options for patients in Taiwan and aligns with Kissei’s broader strategy to expand its market presence internationally. The approval’s financial impact has already been factored into Kissei’s earnings forecast for the fiscal year ending March 31, 2026.

The most recent analyst rating on (JP:4547) stock is a Hold with a Yen4473.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.

Kissei Pharmaceutical Expands Linzagolix Reach with Canadian Licensing Deal

Kissei Pharmaceutical has entered into a licensing agreement with Searchlight Pharma to develop and commercialize the GnRH antagonist ‘Linzagolix’ in Canada. This agreement allows Kissei to receive upfront, milestone, and royalty payments, while Searchlight will handle the product’s development and sales in Canada. Linzagolix, which targets uterine fibroids and endometriosis, is already launched in Europe and under development in Asia, showcasing Kissei’s strategic efforts to expand its global footprint and strengthen its position in the women’s health market.

The most recent analyst rating on (JP:4547) stock is a Buy with a Yen4943.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.

Kissei Pharmaceutical Completes Sale of Investment Securities

Kissei Pharmaceutical Co., Ltd. has completed the sale of two listed stocks, resulting in a gain of ¥11,605 million. This transaction is part of the company’s strategy to enhance medium- to long-term capital returns by reallocating funds to growth investments, particularly in R&D, without affecting its current earnings forecast.

The most recent analyst rating on (JP:4547) stock is a Buy with a Yen4943.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.

Kissei Pharmaceutical Secures Licensing for TED Treatments in Japan

Kissei Pharmaceutical Co., Ltd. has entered into a licensing agreement with Viridian Therapeutics to acquire exclusive development and sales rights for veligrotug and VRDN-003 in Japan, both of which are potential treatments for thyroid eye disease (TED). This strategic move aligns with Kissei’s medium-term management plan ‘Beyond 80’, aimed at growth and expanding its research and development pipeline, particularly in the area of rare diseases. The agreement is expected to enhance Kissei’s market positioning in Japan and contribute to the treatment of TED, a condition with significant unmet medical needs.

The most recent analyst rating on (JP:4547) stock is a Hold with a Yen3600.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.

Kissei Pharmaceutical Revises Financial Forecast and Records Extraordinary Income

Kissei Pharmaceutical Co. has revised its financial forecast for the fiscal year ending March 31, 2026, due to a new technology licensing agreement that increases R&D expenses, impacting operating and ordinary profits. Despite this, the company expects to maintain its profit forecast by recording extraordinary income from the sale of investment securities, aimed at improving capital efficiency and funding growth investments.

The most recent analyst rating on (JP:4547) stock is a Hold with a Yen3600.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.

Kissei Pharmaceutical Reports Q1 Financial Results with Increased Sales

Kissei Pharmaceutical reported a 4.9% increase in net sales for the three months ending June 30, 2025, compared to the same period in the previous year. Despite the rise in sales, the operating profit saw a slight decline of 2.3%. The company forecasts a modest growth in profit attributable to owners for the fiscal year ending March 31, 2026, indicating a stable outlook amidst industry challenges.

The most recent analyst rating on (JP:4547) stock is a Hold with a Yen3600.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.